Moat.
Speed.
Allocation.
The platform moat that survives 2028 is being chosen this year.
This briefing tells you which platform moats survive 2028 in medtech as AI rewrites build economics. Read it before your R&D allocation locks for the decade.
The 10-page briefing. Worth 20 minutes.
One email. One PDF. Worth twenty minutes of your week.
We send it once. Work emails only.
Monday 9:15, R&D review. Firmware sprint velocity up nineteen percent quarter on quarter. Submission-documentation agents cut GSPR assembly time by sixty percent. Your VP Engineering opens the dashboard. He is mid-sentence when your phone buzzes. The CMIO at your biggest hospital system: "We are piloting Aidoc on three imaging workflows, happy to talk about integration." Your Head of Regulatory Affairs mentioned a recruiter call from RegDesk over coffee Thursday. Your CEO has a CAIO shortlist from the board on his desk.
You are not running one R&D function. You are running two, and only one is on your scorecard. One funds the next generation of the existing device through the existing regulatory pathway. The other funds what has to exist by 2028: the clinical-evidence engine, the installed-base telemetry platform, the data rights you have not renegotiated with your top hospital systems.
The moat that matters in 2028 is not above the model layer. It is underneath it.
This is the question your CEO is already asking. The briefing below is what you want in your hand before the next R&D review.
Build Velocity. Product Defensibility. R&D Capital Allocation.
Three questions every medtech CTO is tracking. The third is the crux. The first two are how you earn the right to answer it.
Is our engineering speed shipping submission-grade output, or demos that fail the notified body?
Firmware Copilot at seventy percent. Submission-assembly sixty percent faster. Evidence documentation lags the code. A competitor reached 510(k) six months faster not because their team was smarter, but because their regulatory knowledge was systematic.
What does our portfolio do that an AI-native diagnostic at ten percent of our submission cost cannot copy?
Your device-feature edge commoditises every eighteen months when the next foundation model rolls. Your installed-base telemetry and clinical-data graph compound. Your notified body relationship sits in one RA director's head, and a regulatory-AI vendor called last month.
Is our R&D budget one instrument or two?
One funds the existing device through the next submission. The other builds the 2028 moat. On one hurdle rate the first wins every quarter. On one scorecard the second does not exist. The CTO who walks in with one budget runs the same programme every peer is running.
What you get when you download
An 11-page report for CTOs, CPOs, and Heads of R&D at mid-market European medtech firms. Designed to be read in one sitting before your next R&D review.
Your industry, your R&D function, and why they are one problem
What is happening to mid-market medtech: AI-native diagnostics at ten percent of your submission cost, the device-feature layer commoditising every eighteen months, and named hospital pilots opening with subscription-priced competitors. What is happening inside your R&D function: firmware Copilot up, IEC 62304 review lagging, the junior pathway collapsed, and the board AI-strategy ownership list your seat is not on.
Four moves across build engine, platform and data, product thesis, and R&D bench
Instrument review depth per firmware change and separate business-layer AI from regulated-submission AI. Build the moat underneath the device layer through installed-base telemetry, the clinical-data graph, and integration depth published for top hospital IT systems. Stand one subscription-priced line on protected P&L. Rebuild the junior pathway around senior and agent pairing.
Five questions for your next R&D review
Is your R&D budget one instrument or two, and what is the kill criterion on each? Name the AI-native diagnostic in your category and the percent of your submission cost they clear at. How many months to reconstruct the notified body relationship if your Head of Regulatory Affairs leaves tomorrow? Where did the freed hours from RegDesk go? Is your Q1 boundary agreement with the CEO written?
Calibrated for each seat at the table.